ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today results from a retrospective post-hoc analysis of its phase 3 pivotal EF-14 trial data showing that increased compliance ...
EF-19 data confirm the effectiveness and safety of Optune as monotherapy and further strengthen Optune’s clinical profile in recurrent GBM The FDA-mandated EF-19 post-approval registry trial studied ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly ...
Despite an expected 7% revenue growth for FY2025, NVCR stock price was cut in half in 2025 following the disappointing adoption of Optune Lua in the US and Germany. Yet, the company pipeline has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results